Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-11-07
|
Spinraza™ (nusinersen - ISIS-SMNRx - antisense oligonucleotide targeted to the SMN2 gene) |
spinal muscular atrophy |
3 |
Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) |
Neuromuscular diseases - Rare diseases - Genetic diseases |
2016-11-07
|
SynGEM® |
Respiratory Syncytial Virus (RSV) infection |
1 |
Mucosis (The Netherlands) |
Infectious diseases |
2016-11-07
|
CK?2018571 (CK-571) |
|
preclinical |
Cytokinetics (USA - CA) |
Lung diseases - Respiratory diseases |
2016-11-04
|
Livatag® (doxorubicin Transdrug®) |
pancreatic cancer |
preclinical |
Onxeo (France) |
Cancer - Oncology |
2016-11-03
|
emricasan |
NASH (non-alcoholic steatohepatitis) |
2 |
Conatus Pharmaceuticals (USA - CA) |
Hepatic diseases - Liver diseases |
2016-11-03
|
AGS-003 |
metastatic renal cell carcinoma (mRCC) |
2 |
Argos Therapeutics (USA - NC) |
Cancer - Oncology |
2016-11-03
|
BL-8040 |
acute myeloid leukemia (AML) |
2a |
BioLineRx (Israel) |
Cancer - Oncology |
2016-11-02
|
BP1001 (liposomal Grb2 antisense oligonucleotide) |
acute myeloid leukemia (AML) |
2 |
Bio-Path Holdings (USA - TX) |
Cancer - Oncology |
2016-11-02
|
M834 |
|
1 |
Mylan (USA - PA) Momenta Pharmaceuticals (USA - MA) |
|
2016-11-02
|
baricitinib (LY3009104) |
rheumatoid arthritis |
3 |
Eli Lilly (USA - IN) Incyte Corporation (USA - DE) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-11-02
|
glesatinib, sitravatinib or mocetinostat in combination with nivolumab |
non-small cell lung cancer (NSCLC) |
2 |
Mirati Therapeutics (USA - CA) |
Cancer - Oncology |
2016-11-01
|
NVP018 |
NASH (non-alcoholic steatohepatitis) |
preclinical |
Neurovive Pharmaceutical (Sweden) |
Liver diseases - Hepatic diseases |
2016-11-01
|
bococizumab |
hyperlipidemia |
3 |
Pfizer (USA - NY) |
Cardiovascular diseases - Metabolic diseases |
2016-11-01
|
IONIS-FXIRx |
patients with end-stage renal disease (ESRD) on hemodialysis |
2 |
Ionis Pharmaceuticals (USA - CA) |
Renal diseases - Kidney diseases |
2016-10-31
|
E2609 |
Alzheimer's disease |
3 |
Eisai (Japan) |
Neurodegenerative diseases |
2016-10-31
|
telotristat etiprate |
carcinoid syndrome patients with metastatic neuroendocrine tumor (NET) inadequately controlled by somatostatin analog (SSAs) |
3 |
Ipsen (France) Lexicon Pharmaceuticals (USA - TX) |
Cancer - Oncology |
2016-10-28
|
Tcelna (imilecleucel-T) |
secondary progressive multiple sclerosis |
2 |
Opexa Therapeutics (USA - TX) |
Autoimmune diseases - Neurodegenerative diseases |
2016-10-28
|
lemborexant (E2006) |
patients with Irregular Sleep-Wake Rhythm Disorder and mild to moderate Alzheimer’s disease dementia |
2 |
Eisai (Japan) |
Neurodegenerative diseases - Neurological diseases |
2016-10-27
|
Beleodaq™ (belinostat) and immune checkpoint inhitors |
|
preclinical |
Onxeo (France) |
Cancer - Oncology |
2016-10-27
|
HinsBet® U100 |
type 1 diabetes |
1-2a |
Adocia (France) |
Metabolic diseases |